The use of medication for the treatment of attention deficit disorders, such as ADHD, is growing. The recent recognition of ADHD as a condition that can also afflict adults has provided a boon to the industry, and healthcare reform has enabled more children to access behavioral health services, resulting in more patients being able to have their ADHD identified and treated. In the five years to 2021, industry revenue will continue to grow as the trends from the previous five years bolster utilization rates. However, many brand-name drugs are set to lose their patent exclusivity, which will incite more generic drug manufacturers to inundate the market with low-cost drugs, intensifying price-based competition.
This industry manufactures medications that treat people with attention deficits, such as attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD).
This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.